Fig. 5

TET1 inhibition confers cytotoxic effect on both SmoA1- and human MBs. a mRNA Tet1 and Tet2 expression upon shRNA treatment targeting Tet1 in primary cultures of SmoA1-MBs. Expression was normalized with Gapdh expression (* indicates p < 0.05 and ** indicates p < 0.01). b Relative cell viability in 5 days of two different sh-Tet1-treated primary cells compared to sh-scrambled-treated primary cells for three biological replicates (** indicates p < 0.01 and *** indicates p < 0.001). c Left: structure of TET1 inhibitor UC-514321. Right: dose-dependent expression of Tet1 2 days after chemical treatment (0 nM, 100 nM, and 200 nM, respectively, p < 0.0001 for both). d Relative cell viability depending on dose of drug (nM) in SmoA1^+/+. NSC: Neuronal stem cell. e mRNA Tet1 expression upon 200 nM of UC-514321 treatment in MB cell lines, including Daoy (p < 0.05), ONS-76 (p < 0.05), D556 (p < 0.001), and D425 (no significance). f Relative cell viability depending on dose of drug (nM) in MB cell lines. g Volcano plot showing RNA-seq data of 2 DMSO-treated and drug-treated primary cultures of SmoA1-MBs. Purple dots indicate upregulated transcripts, and red dots indicate downregulated transcripts 2 days after TET1 inhibitor treatment. Transcripts with absolute fold change > 2 and adjusted p value < 0.05 are considered statistically significant. h Genes significantly downregulated after TET1 inhibitor treatment (absolute fold change > 2 and FDR < 0.05). i PANTHER pathway analysis using downregulated genes after TET1 inhibitor treatment